Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31397083 | 0.88 | DDB1 (0.56) | DDB1CRBNHDAC6 | |
| SCHEMBL31397472 | 0.84 | DDB1 (0.49) | DDB1CRBNWNT1GSK3BDYRK1A | |
| SCHEMBL23540810 | 0.84 | CRBN (0.56) | DDB1CRBN | |
| SCHEMBL31396982 | 0.83 | DDB1 (0.49) | DDB1CRBN | |
| SCHEMBL23541274 | 0.83 | DDB1 (0.49) | DDB1CRBNWNT1GSK3BDYRK1A | |
| SCHEMBL30273602 | 0.83 | DDB1 (0.53) | DDB1CRBN | |
| SCHEMBL30289471 | 0.82 | DDB1 (0.54) | DDB1CRBN | |
| SCHEMBL23540624 | 0.82 | DDB1 (0.49) | DDB1CRBNWNT1GSK3BDYRK1A | |
| SCHEMBL30938959 | 0.81 | DDB1 (0.55) | DDB1CRBN | |
| SCHEMBL23842106 | 0.81 | DDB1 (0.64) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | DDB1 2296/4885CRBN 161/4885HDAC6 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.